Patents Assigned to Probiocon GmbH
  • RANKL-specific agent for treating metastatic disease
    Patent number: 12048744
    Abstract: The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: July 30, 2024
    Assignee: Probiocon GmbH
    Inventors: Helmut Salih, Ludger Grosse-Hovest, Andreas Herrmann, Hans-Georg Kopp, Stefanie Maurer
  • RANKL-specific agent for treating metastatic disease
    Patent number: 10806786
    Abstract: The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: October 20, 2020
    Assignee: Probiocon GmbH
    Inventors: Helmut Salih, Ludger Grosse-Hovest, Andreas Herrmann, Hans-Georg Kopp, Stefanie Maurer
  • RANKL-SPECIFIC AGENT FOR TREATING METASTATIC DISEASE
    Publication number: 20170319687
    Abstract: The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.
    Type: Application
    Filed: November 12, 2015
    Publication date: November 9, 2017
    Applicant: Probiocon GmbH
    Inventors: Helmut SALIH, Ludger GROSSE-HOVEST, Andreas HERRMANN, Hans-Georg KOPP, Stefanie RAAB